Artwork

Content provided by Toby Pasman. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Toby Pasman or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Christopher J. Moreau: DMT, Neuroplasticity & Stroke Recovery | Episode 200

45:20
 
Share
 

Manage episode 349098991 series 2937889
Content provided by Toby Pasman. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Toby Pasman or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Mr. Moreau is the CEO of Algernon Pharmaceuticals Inc. and a member of the company's board of directors. With over 30 years of executive management experience overall, including 15 years in CEO roles, he has proven achievements in operations management, acquisitions, licensing, and integration.
Algernon Pharmaceuticals plans to be the first Company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible this year. DMT is a "classic" psychedelic compound part of the tryptamine family.
https://algernonpharmaceuticals.com

  continue reading

226 episodes

Artwork
iconShare
 
Manage episode 349098991 series 2937889
Content provided by Toby Pasman. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Toby Pasman or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Mr. Moreau is the CEO of Algernon Pharmaceuticals Inc. and a member of the company's board of directors. With over 30 years of executive management experience overall, including 15 years in CEO roles, he has proven achievements in operations management, acquisitions, licensing, and integration.
Algernon Pharmaceuticals plans to be the first Company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible this year. DMT is a "classic" psychedelic compound part of the tryptamine family.
https://algernonpharmaceuticals.com

  continue reading

226 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide